Reports of Biochemistry
and Molecular Biology
Wed, Jul 30, 2025
[Archive]
Volume 13, Issue 4 (Vol.13 No.4 Jan 2025)
rbmb.net 2025, 13(4): 507-515 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Karimzadeh M R, Najmadini A, Azhdari S, Zatalian N, Zandi F, Salmani N et al . Association of Alzheimer's Disease with Promoter Variations in NPY2R Gene. rbmb.net 2025; 13 (4) :507-515
URL: http://rbmb.net/article-1-1197-en.html
URL: http://rbmb.net/article-1-1197-en.html
Mohammad Reza Karimzadeh 
, Atefeh Najmadini , Sara Azhdari , Negin Zatalian , Fatemeh Zandi , Neda Salmani , Kolsoum Saeidi *
, Atefeh Najmadini , Sara Azhdari , Negin Zatalian , Fatemeh Zandi , Neda Salmani , Kolsoum Saeidi *
Neurology Research Center, Kerman University of Medical Sciences, Kerman, Iran.
Abstract: (238 Views)
Background: Alzheimer's disease (AD) is a widespread neurodegenerative disorder among the elderly, characterized by dementia. The development of AD is significantly influenced by genetic risk factors.
Methods: in this study, we have investigated the impact of rs2234759 and rs12507396 polymorphisms in the neuropeptide Y receptor Y2 (NPY2R) gene on AD. Nineteen AD patients and nineteen healthy controls were enlisted in our research. and the DNA samples of all participants were genotyped using amplification refractory mutation system-polymerase chain reaction (ARMS-PCR).
Results: The results revealed a noteworthy association between rs2234759 and AD, with a noticeable difference observed in the frequency of genotypes and alleles of this polymorphism between patients and healthy controls (P< 0.001 for both). However, no significant difference was detected in the genotype distribution concerning the rs12507396 polymorphism between the two groups.
Conclusion: Our findings provide compelling evidence of an association between the rs2234759 polymorphism in NPY2R and Alzheimer's disease. Given the significant role of NPY2R in brain tissue, this particular polymorphism may result in strengthened presynaptic inhibition of glutamate release.
Methods: in this study, we have investigated the impact of rs2234759 and rs12507396 polymorphisms in the neuropeptide Y receptor Y2 (NPY2R) gene on AD. Nineteen AD patients and nineteen healthy controls were enlisted in our research. and the DNA samples of all participants were genotyped using amplification refractory mutation system-polymerase chain reaction (ARMS-PCR).
Results: The results revealed a noteworthy association between rs2234759 and AD, with a noticeable difference observed in the frequency of genotypes and alleles of this polymorphism between patients and healthy controls (P< 0.001 for both). However, no significant difference was detected in the genotype distribution concerning the rs12507396 polymorphism between the two groups.
Conclusion: Our findings provide compelling evidence of an association between the rs2234759 polymorphism in NPY2R and Alzheimer's disease. Given the significant role of NPY2R in brain tissue, this particular polymorphism may result in strengthened presynaptic inhibition of glutamate release.
Type of Article: Original Article |
Subject:
Molecular Biology
Received: 2023/06/27 | Accepted: 2023/09/15 | Published: 2025/07/30
Received: 2023/06/27 | Accepted: 2023/09/15 | Published: 2025/07/30
References
1. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709-17. [DOI:10.1523/JNEUROSCI.2177-05.2005] [PMID] []
2. Jessen F, Amariglio RE, van Boxtel M, Breteler M, Ceccaldi M, Chételat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10(6):844-52. [DOI:10.1016/j.jalz.2014.01.001] [PMID] []
3. Dubois B, Feldman HH, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol. 2007;6(8):734-46. [DOI:10.1016/S1474-4422(07)70178-3] [PMID]
4. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008;23(5):537-45. [DOI:10.1002/gps.1949] [PMID]
5. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314(5800):777-81. [DOI:10.1126/science.1132814] [PMID]
6. Chan HH, Leong YQ, Voon SM, Pan ML, Leong CO, Lim CL, Koh RY. Effects of Amyloid Precursor Protein Overexpression on NF-κB, Rho-GTPase and Pro-Apoptosis Bcl-2 Pathways in Neuronal Cells. Rep Biochem Mol Biol. 2021;9(4):417-425. [DOI:10.52547/rbmb.9.4.417] [PMID] []
7. Biglari S, Kamali K, Banihashemi S, Faal Sezavari A, Aghajanpour-Mir SM, Behjati F. Investigation of Aneusomy of Chromosome 21 in the Micronuclei of 13 Patients with Early Onset Alzheimer's Disease Using Fluorescence in Situ Hybridization: A Pilot Study. Rep Biochem Mol Biol. 2020;8(4):446-453.
8. Raux G, Guyant-Maréchal L, Martin C, Bou J, Penet C, Brice A, et al. Molecular diagnosis of autosomal dominant early onset Alzheimer's disease: an update. J Med Genet. 2005;42(10):793-5. [DOI:10.1136/jmg.2005.033456] [PMID] []
9. Rovelet-Lecrux A, Hannequin D, Raux G, Le Meur N, Laquerrière A, Vital A, et al. APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet. 2006;38(1):24-6. [DOI:10.1038/ng1718] [PMID]
10. Coon KD, Myers AJ, Craig DW, Webster JA, Pearson JV, Lince DH, et al. A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry. 2007;68(4):613-8. [DOI:10.4088/JCP.v68n0419] [PMID]
11. Zhang B, Gaiteri C, Bodea LG, Wang Z, McElwee J, Podtelezhnikov AA, et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell. 2013;153(3):707-20. [DOI:10.1016/j.cell.2013.03.030] [PMID] []
12. Scheff SW, Price DA, Schmitt FA, Mufson EJ. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol Aging. 2006;27(10):1372-84. [DOI:10.1016/j.neurobiolaging.2005.09.012] [PMID]
13. Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R. Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging. 2011;32(5):802-10. [DOI:10.1016/j.neurobiolaging.2009.05.002] [PMID]
14. Vezzani A, Sperk G. Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy? Neuropeptides. 2004;38(4):245-52. [DOI:10.1016/j.npep.2004.05.004] [PMID]
15. Xapelli S, Silva AP, Ferreira R, Malva JO. Neuropeptide Y can rescue neurons from cell death following the application of an excitotoxic insult with kainate in rat organotypic hippocampal slice cultures. Peptides. 2007;28(2):288-94. [DOI:10.1016/j.peptides.2006.09.031] [PMID]
16. Ammar DA, Eadie DM, Wong DJ, Ma YY, Kolakowski LF Jr, Yang-Feng TL, Thompson DA. Characterization of the human type 2 neuropeptide Y receptor gene (NPY2R) and localization to the chromosome 4q region containing the type 1 neuropeptide Y receptor gene. Genomics. 1996;38(3):392-8. [DOI:10.1006/geno.1996.0642] [PMID]
17. Rose PM, Fernandes P, Lynch JS, Frazier ST, Fisher SM, Kodukula K, et al. Cloning and functional expression of a cDNA encoding a human type 2 neuropeptide Y receptor. J Biol Chem. 1995;270(39):22661-4. [DOI:10.1074/jbc.270.39.22661] [PMID]
18. Broberger C, Landry M, Wong H, Walsh JN, Hökfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology. 1997;66(6):393-408. [DOI:10.1159/000127265] [PMID]
19. Gerald C, Walker MW, Vaysse PJ, He C, Branchek TA, Weinshank RL. Expression cloning and pharmacological characterization of a human hippocampal neuropeptide Y/peptide YY Y2 receptor subtype. J Biol Chem. 1995;270(45):26758-61. [DOI:10.1074/jbc.270.45.26758] [PMID]
20. Morales-Medina JC, Dumont Y, Quirion R. A possible role of neuropeptide Y in depression and stress. Brain Res. 2010;1314:194-205. [DOI:10.1016/j.brainres.2009.09.077] [PMID]
21. Rose JB, Crews L, Rockenstein E, Adame A, Mante M, Hersh LB, et al. Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J Neurosci. 2009;29(4):1115-25. [DOI:10.1523/JNEUROSCI.4220-08.2009] [PMID] []
22. Kloster E, Saft C, Akkad DA, Epplen JT, Arning L. Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R. J Mol Med (Berl). 2014;92(2):177-84. [DOI:10.1007/s00109-013-1092-3] [PMID]
23. Silva AP, Pinheiro PS, Carvalho AP, Carvalho CM, Jakobsen B, Zimmer J, Malva JO. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J. 2003;17(9):1118-20. [DOI:10.1096/fj.02-0885fje] [PMID]
24. Arning L, Stock AK, Kloster E, Epplen JT, Beste C. NPY2-receptor variation modulates iconic memory processes. Eur Neuropsychopharmacol. 2014;24(8):1298-302. [DOI:10.1016/j.euroneuro.2014.03.003] [PMID]
25. Lu ZL, Neuse J, Madigan S, Dosher BA. Fast decay of iconic memory in observers with mild cognitive impairments. Proc Natl Acad Sci U S A. 2005;102(5):1797-802. [DOI:10.1073/pnas.0408402102] [PMID] []
26. Penner J, Rupsingh R, Smith M, Wells JL, Borrie MJ, Bartha R. Increased glutamate in the hippocampus after galantamine treatment for Alzheimer disease. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(1):104-10. [DOI:10.1016/j.pnpbp.2009.10.007] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
